- Home
- AUTL vs ARDC Comparison
AUTL vs ARDC Comparison
Compare AUTL & ARDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- ARDC
- Stock Information
- Founded
- AUTL 2014
- ARDC 2012
- Country
- AUTL United Kingdom
- ARDC United States
- Employees
- AUTL N/A
- ARDC N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- ARDC Investment Managers
- Sector
- AUTL Health Care
- ARDC Finance
- Exchange
- AUTL Nasdaq
- ARDC Nasdaq
- Market Cap
- AUTL 360.6M
- ARDC 330.8M
- IPO Year
- AUTL 2018
- ARDC N/A
- Fundamental
- Price
- AUTL $1.51
- ARDC $13.41
- Analyst Decision
- AUTL Strong Buy
- ARDC
- Analyst Count
- AUTL 5
- ARDC 0
- Target Price
- AUTL $9.32
- ARDC N/A
- AVG Volume (30 Days)
- AUTL 2.0M
- ARDC 115.8K
- Earning Date
- AUTL 05-08-2025
- ARDC 01-01-0001
- Dividend Yield
- AUTL N/A
- ARDC 9.84%
- EPS Growth
- AUTL N/A
- ARDC N/A
- EPS
- AUTL N/A
- ARDC N/A
- Revenue
- AUTL $10,120,000.00
- ARDC N/A
- Revenue This Year
- AUTL $277.74
- ARDC N/A
- Revenue Next Year
- AUTL $221.89
- ARDC N/A
- P/E Ratio
- AUTL N/A
- ARDC N/A
- Revenue Growth
- AUTL 496.00
- ARDC N/A
- 52 Week Low
- AUTL $1.11
- ARDC $11.56
- 52 Week High
- AUTL $5.00
- ARDC $14.30
- Technical
- Relative Strength Index (RSI)
- AUTL 49.38
- ARDC 47.02
- Support Level
- AUTL $1.32
- ARDC $13.04
- Resistance Level
- AUTL $1.45
- ARDC $13.31
- Average True Range (ATR)
- AUTL 0.16
- ARDC 0.43
- MACD
- AUTL 0.04
- ARDC 0.07
- Stochastic Oscillator
- AUTL 65.85
- ARDC 76.21
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About ARDC Ares Dynamic Credit Allocation Fund Inc.
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).